Treatment Outcomes And Prognosis Of Peripheral T-Cell Lymphoma, Not Otherwise Specified
X.W. Deng,Y. Li,X. Zhang,J. Jin,W. Wang,S. Wang,H. Fang,H. Ren,Yun-Bao Liu,Mei Dong,Y. Song
DOI: https://doi.org/10.1016/j.ijrobp.2015.07.1713
2015-01-01
Abstract:The optimal therapy and prognosis for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) are not well defined. This study was conducted to evaluate the treatment outcomes and prognostic factors in patients with PTCL-NOS. 119 patients who were diagnosed with PTCL-NOS between January 1998 and December 2014 were reviewed. There were 19, 31, 33, and 36 patients with stage I, stage II, stage III, and stage IV diseases, respectively. Of patients with stage I and II, 31 received radiation therapy with or without chemotherapy (RT w/o CT), 18 received combination chemotherapy. All 69 patients with stage III/IV received primary chemotherapy. Of patients receiving chemotherapy, 27 were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), 19 with CHOEP (CHOP plus etoposide), 9 with gemcitabine-based combination regimen, and 59 with other regimens or multiple regimens due to poor response to first-line chemotherapy. The 5-year overall survival (OS) and progression-free survival (PFS) for all patients were 24% and 15%, respectively. The overall response rate was 63%, with 42% complete remission (CR) rates. Treatments with radiation therapy significantly improved the prognosis compared with chemotherapy alone for early-stage patients. The 5-year cancer-specific survival (CSS) were 44% for RT w/o CT and 13% for chemotherapy alone (P = 0.045), and the 5-year PFS rates was 41% and 13%, respectively (P = 0.044). For patients with early-stage PTCL-NOS who did not achieve CR after initial chemotherapy, radiation therapy effectively improved 5-year OS (P = 0.038), 5-year CSS (P = 0.015) and 5-year PFS (P = 0.014). There was no significant difference between CHOEP regimen and CHOP regimen as to the CR rate (46% versus 47%; P = 0.936) and 5-year OS (37% versus 10%; P = 0.058). However, the addition of etoposide (CHOEP) significantly improved PFS. The 5-year PFS rate for two groups was 21% and 10% (P = 0.030). The B symptoms, advanced stage, elevated lactate dehydrogenase (LDH), non-CR after initial therapy, poor performance status, Ki-67 ≥80%, Platelets count <150×109/L were associated with a poor disease outcome. Both International Prognostic Index (IPI) and Prognostic Index for PTCL-NOS (PIT) were useful in predicting OS (P =0.005 and P =0.002) and PFS (P =0.012 and P =0.004), but PIT score did better in defining risk groups with significantly different outcomes. Treatments with radiation therapy has a significant impact on outcome for early-stage diseases. Combining etoposide with CHOP proved to be effective in terms of PFS in the initial treatment. However, with the aggressive clinical course and poor outcome, more efficacious treatment strategies are urgently needed.